You are seeing these quotes based on previous browsing related to sectors such as
| Latest | Forecast | |
|---|---|---|
| Div Yield | 2.2% | 2.4% |
| Div Cover | 1.3 | 2.6 |
| Op Mrgn | 17.9% | 29.8% |
| ROCE | 62.6% |
| Latest | Forecast | |
|---|---|---|
| P/E | 33.7 | 0.0 |
| PEG | 0.4 | 0.2 |
| Price / Revenue | 4.4 | 3.0 |
| Price / Book value | 5.1 |
| Latest | Forecast | |
|---|---|---|
| Revenue | 3.3% | 5.3% |
| PBT | 175.8% | n/a |
| EPS | 81.1% | -3.8% |
| DPS | 0.0% | -1.6% |
| Year Ending | Revenue ($m) |
Pre-tax ($m) |
EPS | P/E | PEG | EPS Growth | Div | Yield |
|---|---|---|---|---|---|---|---|---|
| 2019-12-31 | 24,384.00 | 1,548.00 | $1.03 | 97.9 | -2.5 | -39% | $2.80 | 2.8% |
| 2020-12-31 | 26,617.00 | 3,916.00 | $2.44 | 41.0 | 0.3 | 137% | $2.80 | 2.8% |
| 2021-12-31 | 37,417.00 | -265.00 | $0.08 | 1,467.0 | -15.2 | -97% | $2.87 | 2.4% |
| 2022-12-31 | 44,351.00 | 2,501.00 | $2.12 | 64.0 | 0.0 | 2,550% | $2.90 | 2.1% |
| 2023-12-31 | 45,811.00 | 6,899.00 | $3.84 | 35.2 | 0.4 | 81% | $2.90 | 2.1% |
| AstraZeneca cancer drug secures US approval Sharecast News | 05 Dec |
|---|---|
| AstraZeneca appoints Iskra Reic as vice-president of intl unit Sharecast News | 04 Dec |
| AstraZeneca reports positive results from prostate cancer trial Sharecast News | 25 Nov |
| Directorate Change | 16-Dec-24 07:01 |
|---|---|
| Imfinzi approved in US for limited-stage SCLC | 05-Dec-24 07:02 |
| AstraZeneca appoints Iskra Reic EVP International | 04-Dec-24 13:45 |
| Block listing Interim Review | 02-Dec-24 15:05 |
| Total Voting Rights | 02-Dec-24 15:00 |